Medical Faculty, Institute of Immunology, University Duisburg-Essen, Essen, Germany.
Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Front Immunol. 2020 Aug 21;11:1849. doi: 10.3389/fimmu.2020.01849. eCollection 2020.
Immune activation within the tumor microenvironment is one promising approach to induce tumor regression. Certain viruses including oncolytic viruses such as the herpes simplex virus (HSV) and non-oncolytic viruses such as the lymphocytic choriomeningitis virus (LCMV) are potent tools to induce tumor-specific immune activation. However, not all tumor types respond to viro- and/or immunotherapy and mechanisms accounting for such differences remain to be defined. In our current investigation, we used the non-cytopathic LCMV in different human melanoma models and found that melanoma cell lines produced high levels of CCL5 in response to immunotherapy. , robust CCL5 production in LCMV infected Ma-Mel-86a tumor bearing mice led to recruitment of NK cells and fast tumor regression. Lack of NK cells or CCL5 abolished the anti-tumoral effects of immunotherapy. In conclusion, we identified CCL5 and NK cell-mediated cytotoxicity as new factors influencing melanoma regression during virotherapy.
肿瘤微环境中的免疫激活是诱导肿瘤消退的一种很有前途的方法。某些病毒,包括溶瘤病毒(如单纯疱疹病毒[HSV])和非溶瘤病毒(如淋巴细胞性脉络丛脑膜炎病毒[LCMV]),是诱导肿瘤特异性免疫激活的有效工具。然而,并非所有肿瘤类型都对病毒和/或免疫治疗有反应,解释这种差异的机制仍有待确定。在我们目前的研究中,我们使用非细胞病变性 LCMV 在不同的人黑色素瘤模型中发现,黑色素瘤细胞系对免疫治疗产生高水平的 CCL5。在感染 LCMV 的 Ma-Mel-86a 荷瘤小鼠中,强大的 CCL5 产生导致 NK 细胞的募集和肿瘤的快速消退。缺乏 NK 细胞或 CCL5 会消除免疫治疗的抗肿瘤作用。总之,我们确定 CCL5 和 NK 细胞介导的细胞毒性是影响病毒治疗期间黑色素瘤消退的新因素。